Comparative Pharmacology
Head-to-head clinical analysis: DI ATRO versus LOMOTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DI ATRO versus LOMOTIL.
DI-ATRO vs LOMOTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ipratropium bromide is an anticholinergic agent that antagonizes muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in bronchial smooth muscle, thereby inhibiting vagally-mediated bronchoconstriction and reducing mucus secretion. Albuterol sulfate is a beta-2 adrenergic receptor agonist that activates adenylyl cyclase, increasing cyclic AMP levels, leading to bronchodilation.
Diphenoxylate is a meperidine congener that acts as an opioid receptor agonist, inhibiting gastrointestinal motility and prolonging transit time; atropine is added to discourage abuse at high doses.
Ipratropium bromide inhalation aerosol: 500 mcg (2 puffs) 3-4 times daily; maximum 2000 mcg (8 puffs) per day. Ipratropium bromide nebulizer solution: 500 mcg per nebulization 3-4 times daily.
Adults: 2 tablets (2.5 mg diphenoxylate/0.025 mg atropine) orally four times daily until control of diarrhea is achieved; maintenance dose is 2 tablets once or twice daily. Maximum dose: 8 tablets (20 mg diphenoxylate) per day.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Diphenoxylate: 2.5-3.5 hours; Difenoxin (active metabolite): 12-24 hours. Clinically, antidiarrheal effect is prolonged due to metabolite accumulation.
Renal (80% as unchanged drug), biliary/fecal (20%)
Primarily renal (50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary excretion).
Category C
Category C
Antidiarrheal
Antidiarrheal